EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

A Real-World Study of Nefecon for IgA Nephropathy: Clinical Efficacy, Biomarkers, and Microbiome

Jingjing Ren, Dan Yu, Bo Huang, Ruitong Li, Ranran Wang, Tiantian Zhao, Yibing Chen, Sisi Shen, Tianhao Jiang, Zhanzheng Zhao, Junjun Zhang

Clinical Kidney Journal · 02.11.2026

DOI: 10.1093/ckj/sfag381 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Kidney Journal, online erschienen am 02.11.2026. Verfasst von Jingjing Ren und 10 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Nefecon, a targeted-release budesonide, is the first approved therapy for IgA nephropathy (IgAN) targeting intestinal Peyer’s patches. However, real-world data on its efficacy, biomarker changes, and effects on gut and oral microbiota remain limited.

Methods

We enrolled 87 adults with primary IgAN receiving Nefecon for ≥ 6 months. Clinical indicators and serum, urine, saliva, and fecal samples were collected. We assessed efficacy and safety, analyzed changes in serum and urinary biomarkers and their correlation with clinical response, and evaluated microbiota changes using 16S rRNA sequencing. To account for potential confounding by concomitant immunosuppressants and SGLT2 inhibitors, multivariable linear mixed models (LMM) were applied.

Results

Nefecon was associated with significant reductions in median UTP and URBC at months 3, 6, and 9 (all q < 0.05). After adjusting for baseline covariates including immunosuppressants and SGLT2i, the time-dependent UTP reduction remained significant (F (2 174) = 5.239, P = 0.006). eGFR increased at month 3 (q = 0.018), but the change at month 9 was not significant after FDR correction (q = 0.062). In 18 patients with baseline eGFR 15–35 mL/min/1.73 m², eGFR remained stable and UTP showed a numerical decline of 22.86% at month 9. No severe infections or serious adverse events occurred. Serum Gd-IgA1, polymeric IgA, total IgA, and BAFF decreased. The urinary Gd-IgA1 to creatinine ratio slope moderately correlated with UTP slope (R = 0.510, P < 0.01), whereas serum Gd-IgA1 slope showed weak correlation (R = 0.124, P = 0.466). Intestinal microbiota diversity remained stable, while a decrease in Akkermansia was observed at month 9, along with suppression of oral opportunistic pathogens.

Conclusion

In this real-world IgAN cohort, Nefecon was associated with significant proteinuria reduction and stable renal function. Urinary Gd-IgA1 to creatinine ratio may serve as an exploratory biomarker.

Zitieren

APA

Ren, J., Yu, D., Huang, B., Li, R., Wang, R., Zhao, T., Chen, Y., Shen, S., Jiang, T., Zhao, Z., & Zhang, J. (2026). A Real-World Study of Nefecon for IgA Nephropathy: Clinical Efficacy, Biomarkers, and Microbiome. Clinical Kidney Journal. https://doi.org/10.1093/ckj/sfag381

Vancouver

Ren J, Yu D, Huang B, Li R, Wang R, Zhao T, et al. A Real-World Study of Nefecon for IgA Nephropathy: Clinical Efficacy, Biomarkers, and Microbiome. Clinical Kidney Journal. 2026. doi:10.1093/ckj/sfag381

BibTeX
@article{Ren2026,
  author = {Ren, Jingjing and Yu, Dan and Huang, Bo and Li, Ruitong and Wang, Ranran and Zhao, Tiantian and Chen, Yibing and Shen, Sisi and Jiang, Tianhao and Zhao, Zhanzheng and Zhang, Junjun},
  title = {A Real-World Study of Nefecon for IgA Nephropathy: Clinical Efficacy, Biomarkers, and Microbiome},
  journal = {Clinical Kidney Journal},
  year = {2026},
  doi = {10.1093/ckj/sfag381}
}
Kostenlos starten →